[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602469":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":31,"locations":37,"responsibleParty":61,"collaborators":18,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":18,"enrollmentInfo":75,"targetDuration":18,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":91,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Botkin Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Combination of hemodialysis and hemosorption","EXPERIMENTAL","Dialysis patients will undergo a combined procedure of hemodialysis and hemosorption using the Jafron HA130 cartridge three times per week during the first month, twice per week in the second month, and once per week in the third month.",[13],"Device: Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard hemodialysis procedure","NO_INTERVENTION","Dialysis patients on standard dialysis procedure",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.","The test cartridge will be used in addition to the ongoing program hemodialysis three times a week in the first month, twice a week in the next month, once a week in the third month",[9],[26,27,28,29,30],"Jafron HA130","hemosorption","cartridge for hemosorption","Sorption","Program dialysis",[32],{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},"Evgeny V Shutov, PhD","CONTACT","+79055251002","shutov_e_v@mail.ru",[38],{"facility":5,"status":39,"city":40,"state":18,"zip":18,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Moscow","Russia","RU",{"type":44,"coordinates":45},"Point",[46,47],37.61781,55.75204,{"lat":47,"lon":46},[50,51,55,58,60],{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},{"name":52,"role":34,"phone":53,"phoneExt":18,"email":54},"Stepan A Bolshakov","+79162850296","my@stepan-bolshakov.ru",{"name":56,"role":57,"phone":18,"phoneExt":18,"email":18},"Galina V Kotlyarova","SUB_INVESTIGATOR",{"name":59,"role":57,"phone":18,"phoneExt":18,"email":18},"Dmitry V Fedorov",{"name":52,"role":57,"phone":18,"phoneExt":18,"email":18},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Evgeny Shutov","Head of the Nephrology Center, Botkin Hospital","100602469","studies-on-adsorption-international-learning-initiative-global-100602469",false,"NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy","ALL","18 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"NA","Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[83,84,85,86,87,88,89,90],"CKD (Chronic Kidney Disease) Stage 5D","Uremia; Chronic","Uremic; Toxemia","Inflammation Chronic","Hemodialysis","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[30,29,92],"Complications of program dialysis","2025-12-03",{"date":95,"type":96},"2025-12-10","ACTUAL",{"date":98,"type":96},"2025-06-01",{"date":100,"type":77},"2026-06-30",{"name":5,"class":6},1]